Sunday, October 4, 2026
ExploreSearch
Via News

financial-regulation

2 articles

U.S. Ratings Firm's Dual Role Echoes Global Conflict-of-Interest Debate

U.S. Ratings Firm's Dual Role Echoes Global Conflict-of-Interest Debate

The Oasis Group rates wealth management and estate planning vendors while selling consulting services to the same market — a structural conflict regulators worldwide have scrutinized since 2008. The firm's 2026 Peaks for Estate Planning Platforms report is widely cited in fintech circles, raising questions about independence that remain publicly unanswered. No specific incident has been identified, but analysts rate the governance risk as major severity.

LM Salvado•
Texas CEO Nate Paul Convicted of Wire Fraud in $172M Real Estate Scheme

Texas CEO Nate Paul Convicted of Wire Fraud in $172M Real Estate Scheme

Nate Paul, CEO of Austin-based World Class Capital Group, faces mandatory restitution and asset forfeiture after conviction for wire fraud involving falsified loan applications. Federal prosecutors pursue recovery of losses from commercial real estate financing fraud that exploited US banking systems. The case reflects intensified global enforcement against real estate loan fraud, with similar prosecutions rising in UK, Australia, and Canada.

ViaNews Editorial Team•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com